Radiopharmaceutical developer Navidea Biopharmaceuticals is highlighting clinical results regarding its Lymphoseek radiopharmaceutical that have been published in the Annals of Surgical Oncology.
Researchers from the University of California, San Diego compared sentinel lymph node biopsy procedures using Lymphoseek plus vital blue dye to filtered technetium-99m sulfur colloid plus the dye in breast cancer patients (Ann Surg Oncol, January 2015, Vol. 22:1, pp. 40-45).
Dr. Anne Wallace and colleagues found that Lymphoseek patients had significantly fewer sentinel lymph nodes removed per procedure, fewer nodes were needed to detect cancer spread, and nodes removed using Lymphoseek had greater predictive value for diagnosing the spread of breast cancer to lymph nodes, the company said.
